Lord, Abbett & Co
PBYI icon

Lord, Abbett & Co’s Puma Biotechnology PBYI Stock Holding History

Lord, Abbett & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-150,259
Closed -$35.5M – 968
2015
Q1 		$35.5M Buy
150,259
+66,109
+79% +$14.1M 0.09% 348
2014
Q4 		$15.9M Sell
84,150
-427,566
-84% -$94.9M 0.04% 522
2014
Q3 		$122M Sell
511,716
-843,290
-62% -$173M 0.31% 79
2014
Q2 		$89.3M Sell
1,355,006
-21,053
-2% -$1.5M 0.2% 131
2014
Q1 		$143M Sell
1,376,059
-117,418
-8% -$13.8M 0.33% 83
2013
Q4 		$155M Sell
1,493,477
-107,824
-7% -$6.33M 0.34% 61
2013
Q3 		$85.9M Buy
1,601,301
+1,461,225
+1,043% +$78.8M 0.2% 140
2013
Q2 		$6.21M Buy
+140,076
New +$4.94M 0.01% 749

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Lord, Abbett & Co's PBYI Position: Q2 2015 in Review

Lord, Abbett & Co sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 150,259 shares — an estimated $35.5M sold.

Lord, Abbett & Co first reported a position in PBYI in Q2 2013 and held it in 8 quarters. The position peaked at $155M in Q4 2013. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

  • Lord, Abbett & Co reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 150,259 Puma Biotechnology shares in Q2 2015, an estimated $35.5M.
  • Lord, Abbett & Co first reported a position in Puma Biotechnology in Q2 2013 and held it in 8 quarters.
  • Lord, Abbett & Co's Puma Biotechnology position peaked at $155M in Q4 2013.
  • 198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.